NewsBenzingaIngredion nel terzo trimestre: EPS rettificato a 2,28 dollari, inferiore alla stima di 2,60 dollari; ricavi a 1,792 miliardi di dollari, sotto la stima di 1,802 miliardi di dollari Ingredion nel terzo trimestre: EPS rettificato a 2,28 dollari, inferiore alla stima di 2,60 dollari; ricavi a 1,792 miliardi di dollari, sotto la stima di 1,802 miliardi di dollari Benzinga 2026.11.05 11:05 (GMT+0) Open on Benzinga Other news Global-E Online Stock Is Falling Wednesday: What's Going On? Grifols Presents New Real-World Evidence Data From AMBAR Program, Contributing To Ongoing Research Evaluating Use Of TPE With Albumin Replacement In Patients With Alzheimer’s Disease HC Wainwright & Co. Maintains Buy on LifeMD, Lowers Price Target to $6 Stifel Maintains Buy on Ecolab, Raises Price Target to $356 Stifel Upgrades Tandem Diabetes Care to Buy, Raises Price Target to $26 Immuneering Presents Preclinical Data Demonstrating Potential Of Atebimetinib; Phase 2 Results Include Long Survival And Outstanding Tolerability Profile In First-Line Pancreatic Cancer Patients
Grifols Presents New Real-World Evidence Data From AMBAR Program, Contributing To Ongoing Research Evaluating Use Of TPE With Albumin Replacement In Patients With Alzheimer’s Disease
Immuneering Presents Preclinical Data Demonstrating Potential Of Atebimetinib; Phase 2 Results Include Long Survival And Outstanding Tolerability Profile In First-Line Pancreatic Cancer Patients